EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Initiation of lipid‐lowering therapy as primary prevention of cardiovascular disease in the elderly

José Manuel Vinuesa-Hernando iD, Isabel Aguilar-Palacio iD, María José Rabanaque iD, Victoria García-Cárdenas iD, María Jesús Lallana iD, Adriana Gamba, Sara Malo iD

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16157 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von José Manuel Vinuesa-Hernando und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Primary Prevention, Hypolipidemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Research Group in Health Services in Aragón (GRISSA), Government of Aragón, Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to analyse the initiation adherence phase to lipid‐lowering therapy for primary prevention of cardiovascular disease in a Spanish population aged 70 years or older. The secondary objective was to identify the determinants of initiation and early discontinuation.

Methods

This was an observational study conducted in the CArdiovascular Risk factors for HEalth Service research (CARhES) cohort. People aged 70 and older with a first prescription of a lipid‐lowering drug and without a previous major adverse cardiovascular event (MACE) were selected (2018–2021). Data on sociodemographics, clinical conditions, drugs and use of health services were collected from clinical and administrative electronic databases. The study population was classified into: non‐initiation, early discontinuation (i.e., discontinuation after the first dispensing) and initiation with more than one dispensing. Their characteristics were compared. Determinants of initiation and early discontinuation were explored.

Results

Among the 15 019 people studied, 80.2% initiated the medication, 11.2% showed an early discontinuation and 8.6% were non‐initiators. An older age or conditions such as dementia, diabetes or depression reduced the likelihood of initiation, while obesity and a high pharmacological burden increased it. People over 90 years of age or those prescribed a statin in combination were more likely to have an early discontinuation.

Conclusions

Non‐initiation and early discontinuation are common among older people prescribed lipid‐lowering drugs as primary prevention of cardiovascular disease for the first time. The presence of chronic pathologies other than cardiovascular ones should be considered when assessing whether or not to prescribe these drugs in the elderly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesPrimary PreventionHypolipidemic AgentsHumansAgedMaleFemaleAged, 80 and overSpainHydroxymethylglutaryl-CoA Reductase InhibitorsAge FactorsHeart Disease Risk FactorsDrug Monitoring

Stichwörter der Autor:innen

agedcardiovascular primary preventionhypolipidaemic agentsmedication adherencereal‐world data

Substanzen

Hypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Pharmacy Service, Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain.
  • Department of Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain.
  • Grupo de Investigación en Servicios Sanitarios de Aragón (GRISSA), Fundación Instituto de Investigación Sanitaria de Aragón (IIS Aragón), Zaragoza, Spain.
  • Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), ISCIII, Madrid, Spain.
  • Pharmacy and Pharmaceutical Technology Department, University of Granada, Granada, Spain.
  • Primary Care Pharmacy Service, Sector Zaragoza III, Servicio Aragonés de Salud (SALUD), Zaragoza, Spain.

ORCID-Profile: José Manuel Vinuesa-Hernando, Isabel Aguilar-Palacio, María José Rabanaque, Victoria García-Cárdenas, María Jesús Lallana, Sara Malo

Förderung

  • Instituto de Salud Carlos III
  • Research Group in Health Services in Aragón (GRISSA), Government of Aragón, Spain

Zitieren

APA

Vinuesa-Hernando, J. M., Aguilar-Palacio, I., Rabanaque, M. J., García-Cárdenas, V., Lallana, M. J., Gamba, A., & Malo, S. (2024). Initiation of lipid‐lowering therapy as primary prevention of cardiovascular disease in the elderly. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16157

Vancouver

Vinuesa-Hernando JM, Aguilar-Palacio I, Rabanaque MJ, García-Cárdenas V, Lallana MJ, Gamba A, et al. Initiation of lipid‐lowering therapy as primary prevention of cardiovascular disease in the elderly. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16157

BibTeX
@article{VinuesaHernando2024,
  author = {Vinuesa-Hernando, José Manuel and Aguilar-Palacio, Isabel and Rabanaque, María José and García-Cárdenas, Victoria and Lallana, María Jesús and Gamba, Adriana and Malo, Sara},
  title = {Initiation of lipid‐lowering therapy as primary prevention of cardiovascular disease in the elderly},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16157}
}
Kostenlos starten →